InSightec reports success in essential tremor study

The ExAblate 4000 focused ultrasound device achieved significant improvement in the strength of the tremor.

InSightec Ltd. has reported success in the safety and efficacy clinical trial of its ExAblate 4000 focused ultrasound treatment for the treatment of essential tremor. The trial met its primary endpoints.

The trial included 15 patients at the University of Virginia School of Medicine. Most patients showed significant improvement in the strength of the tremor, and had no side effects. Monitoring of the patients is due to continue for three more months, and the final results of the trial will be due following statistical analysis of the data.

InSightec added that it is also continuing clinical trials of the ExAblate 4000 for the treatment of chronic neuropathic pain and on brain tumors. It is also continuing preclinical studies of the system for the destruction of blood clots, which cause strokes, and for the delivery of medication to the brain.

Elbit Medical Technologies Ltd. (TASE:EMTC), controlled by Mordechay Zisser, owns 64% of InSightec. Elbit Medical's share price rose 9.2% by midday to NIS 0.274, giving a market cap of NIS 220 million.

Published by Globes [online], Israel business news - - on January 3, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018